Axsome Therapeutics (AXSM) Short term Debt: 2022-2025
Historic Short term Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $70.0 million.
- Axsome Therapeutics' Short term Debt rose 760.90% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 760.90%. This contributed to the annual value of $8.3 million for FY2024, which is 29.31% up from last year.
- According to the latest figures from Q3 2025, Axsome Therapeutics' Short term Debt is $70.0 million, which was down 0.00% from $70.0 million recorded in Q2 2025.
- Axsome Therapeutics' 5-year Short term Debt high stood at $70.0 million for Q2 2025, and its period low was $5.9 million during Q4 2022.
- In the last 3 years, Axsome Therapeutics' Short term Debt had a median value of $7.0 million in 2024 and averaged $18.5 million.
- Per our database at Business Quant, Axsome Therapeutics' Short term Debt declined by 4.69% in 2023 and then surged by 894.32% in 2025.
- Axsome Therapeutics' Short term Debt (Quarterly) stood at $5.9 million in 2022, then rose by 8.59% to $6.4 million in 2023, then rose by 29.31% to $8.3 million in 2024, then skyrocketed by 760.90% to $70.0 million in 2025.
- Its Short term Debt stands at $70.0 million for Q3 2025, versus $70.0 million for Q2 2025 and $8.6 million for Q1 2025.